Effect on the cardiovascular independent risk factor lipoprotein(a) in overweight or obese PCOS patients with ethinyl-estradiol/drospirenone alone or plus orlistat.

Muqing GuXiangyan RuanYanqiu LiTianhe LiChenghong YinAlfred O Mueck

Published in: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology (2022)

This is the first study found that EE/DRSP plus Orlistat could significantly decrease Lp(a) in overweight or obese PCOS patients. This result can be assessed as particularly important, because Lp(a) is well-known as an independent risk factor predicting an increased risk of cardiovascular diseases (CVDs).

Keyphrases

weight loss
risk factors
cardiovascular disease
adipose tissue
polycystic ovary syndrome
metabolic syndrome
end stage renal disease
type diabetes
newly diagnosed
ejection fraction
bariatric surgery
weight gain
patient reported outcomes
coronary artery disease
body mass index
cardiovascular risk factors